<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181766</url>
  </required_header>
  <id_info>
    <org_study_id>2003-P-002052</org_study_id>
    <nct_id>NCT00181766</nct_id>
  </id_info>
  <brief_title>Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)</brief_title>
  <official_title>A Pilot Study of Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study with daily doses up to 144 mg/day Strattera (atomoxetine) in the
      treatment of adults with attention deficit hyperactivity disorder not otherwise specified.
      The researchers hypothesize ADHD symptomatology in adults with ADHD NOS will be responsive to
      Strattera treatment and Strattera treatment (in doses of up to 120 mg/day or 1.5 mg/kg/day,
      whichever is less) in adults with ADHD NOS will be safe and well tolerated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Strattera (atomoxetine) is a non-stimulant specific norepinephrine reuptake inhibitor
      recently approved by the Food and Drug Administration for the treatment of child, adolescent
      and adult patients with ADHD. It is possible Strattera could be a viable alternative
      treatment for ADHD individuals. The purpose of this study is to assess the effectiveness,
      safety and tolerability of Strattera in adults with ADHD NOS. If this initial study shows
      promise, we will follow-up with a randomized clinical trial.

      The study includes:

        1. use of a six-week design to document the response rate,

        2. weekly assessments to document the impact of Strattera NOS on functional capacities,

        3. careful assessment of safety and tolerability.

      Primary outcomes measure symptom reduction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD-Clinical Global Impression</measure>
    <time_frame>6 Weeks</time_frame>
    <description>The CGI includes Global Severity (1=not ill; 7=extremely ill) and the Global Improvement (1=very much improved; 7=very much worse) Scales. Overall severity and change in severity of ADHD was assessed with the Clinical Global Impression Scale (CGI). Improvement was defined by CGI-I ≤2, much or very much improved, at study endpoint. Results are given as number of subjects who improved according to the CGI-I using the definition above.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Adult AISRS</measure>
    <time_frame>baseline and 6 Weeks</time_frame>
    <description>The Adult AISRS was used to assess each of the 18 individual criteria symptoms (both inattentive and hyperactive) of ADHD in DSMIV on a severity grid (0=not present; 3=severe; minimum score=0; maximum score=54). Results are given as average change (reduction) in AISRS symptoms from baseline to Week 6.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>ADHD NOS</condition>
  <arm_group>
    <arm_group_label>Strattera (atomoxetine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Strattera (atomoxetine)</intervention_name>
    <description>Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).</description>
    <arm_group_label>Strattera (atomoxetine)</arm_group_label>
    <other_name>Strattera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female outpatients older than 18 and younger than 55 years of age.

          2. Subjects with the diagnosis of attention deficit hyperactivity disorder not otherwise
             specified (ADHD NOS), by Diagnostic and Statistical Manual of Mental Disorders, Fourth
             Edition (DSM-IV), as manifested in clinical evaluation and confirmed by structured
             interview. This is operationalized by either:

               1. having currently at least 6/9 current items of either inattention or
                  hyperactivity/impulsivity but &lt; 5 items from either list in childhood; or

               2. having 5 out of 9 current DSM-IV items of inattention and/or
                  hyperactivity/impulsivity, but not having 6 current symptoms in either category.
                  This second category will be included independent of the presence or absence of
                  ADHD symptoms in childhood.

          3. Subjects will have a current Clinical Global Impression ADHD score of 4 or higher.

          4. Subjects with past history of depression or anxiety disorder (including obsessive
             compulsive disorder [OCD]) without current disorder for &gt; 3 months as ascertained
             through structured diagnostic interview and clinical exam will be allowed to
             participate.

          5. Subjects treated for anxiety disorders and depression who are on a stable medication
             regimen for at least three months, and who have a disorder specific CGI-severity score
             ≤ 3 (mildly ill) and who have a score on the Hamilton-depression and Hamilton-anxiety
             rating scale below 15 (mild range) will be included in the study.

          6. Subjects with past history of substance use disorders but have been asymptomatic for
             at least 6 months and have a negative drug screen will be allowed to participate.

          7. Subjects receiving non-monoamine oxidase inhibitor (MAOI) antidepressants (e.g.,
             selective serotonin reuptake inhibitors [SSRIs], bupropion, venlafaxine), or
             benzodiazepines who have been on a stable regimen for &gt; 3 months for any of the
             conditions listed above.

          8. Subjects with mild cases of asthma and allergy will be allowed to participate.

          9. Subjects with acid reflux syndrome will be allowed to participate.

         10. Subjects with hypercholesterolemia who are on a stable dose of cholesterol-lowering
             medication will be allowed to participate.

        Exclusion Criteria:

          1. Any clinically unstable psychiatric conditions including the following: acute
             psychosis, acute panic, acute OCD, acute mania, acute suicidality, lifetime history of
             bipolar disorder, acute substance use disorders (alcohol or drugs), sociopathy,
             criminality.

          2. Any metabolic, neurological, hepatic, renal, cardiovascular, hematological,
             ophthalmic, or endocrine disease.

          3. Clinically significant abnormal baseline laboratory values which include the
             following:

               1. Values larger than 20% above the upper range of the laboratory standard of a
                  basic metabolic screen.

               2. Exclusionary blood pressure parameters will include any values above 140
                  (systolic) and 90 (diastolic).

               3. Exclusionary electrocardiogram (ECG) parameters will include a QTC &gt; 460 msec,
                  QRS &gt; 120 msec, and PR &gt; 200 msec. Subjects having ECG evidence of ischemia or
                  arrhythmia as reviewed by an independent cardiologist.

          4. Mental retardation (intelligence quotient [I.Q.] &lt; 75).

          5. Organic brain disorders.

          6. Pregnant or nursing females.

          7. Subjects with current adequate treatment for ADHD or a history of a previous adequate
             trial of Strattera.

          8. Subjects who have failed to respond to an adequate trial, or who have had tolerability
             problems on Strattera.

          9. Only English-speaking subjects will be allowed into the study for the following
             reasons:

               1. the assessment instruments are not available and have not been adequately
                  standardized in other languages;

               2. the researchers' clinical trials facility is located in Cambridge and not in the
                  Massachusetts General Hospital (MGH) main campus without the availability of
                  translators;

               3. psychiatric questionnaires and evaluations are taxing and adding the complexity
                  of a translator has the potential to make the patient experience even more
                  exhausting.

         10. Prior hypersensitivity to Strattera.

         11. MAOI antidepressant use currently or within two weeks of starting study.

         12. Urinary retention or bladder dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Wozniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>February 26, 2010</results_first_submitted>
  <results_first_submitted_qc>May 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2010</results_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 27, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Biederman, MD</investigator_full_name>
    <investigator_title>Chief, Clinical and Research Program in Pediatric Psychopharmacology and Adult ADHD; Professor of Psychiatry, Harvard Medical School</investigator_title>
  </responsible_party>
  <keyword>ADHD NOS</keyword>
  <keyword>Adults</keyword>
  <keyword>Strattera (atomoxetine)</keyword>
  <keyword>Open-Label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were from referrals to the Adult ADHD Program at the MGH and through advertisements in the local media. The majority of subjects referred to our program first participate in our general screening protocol entitled, “A Screening Protocol for Adults with Attention Deficit Hyperactivity Disorder” (Protocol # 2002-P-001856).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Strattera (Atomoxetine)</title>
          <description>Atomoxetine monotherapy up o 1.2 mg/kg/day or 120 mg/day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45">Number of subjects enrolled and treated with Atomoxetine.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33">Completed the trial.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Strattera (Atomoxetine)</title>
          <description>Atomoxetine monotherapy up o 1.2 mg/kg/day or 120 mg/day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ADHD-Clinical Global Impression</title>
        <description>The CGI includes Global Severity (1=not ill; 7=extremely ill) and the Global Improvement (1=very much improved; 7=very much worse) Scales. Overall severity and change in severity of ADHD was assessed with the Clinical Global Impression Scale (CGI). Improvement was defined by CGI-I ≤2, much or very much improved, at study endpoint. Results are given as number of subjects who improved according to the CGI-I using the definition above.</description>
        <time_frame>6 Weeks</time_frame>
        <population>All analyses were intention to treat (ITT) with the last observation carried forward (LOCF) for subjects who did not complete the full study schedule.</population>
        <group_list>
          <group group_id="O1">
            <title>Strattera (Atomoxetine)</title>
            <description>Atomoxetine monotherapy up o 1.2 mg/kg/day or 120 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD-Clinical Global Impression</title>
          <description>The CGI includes Global Severity (1=not ill; 7=extremely ill) and the Global Improvement (1=very much improved; 7=very much worse) Scales. Overall severity and change in severity of ADHD was assessed with the Clinical Global Impression Scale (CGI). Improvement was defined by CGI-I ≤2, much or very much improved, at study endpoint. Results are given as number of subjects who improved according to the CGI-I using the definition above.</description>
          <population>All analyses were intention to treat (ITT) with the last observation carried forward (LOCF) for subjects who did not complete the full study schedule.</population>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Adult AISRS</title>
        <description>The Adult AISRS was used to assess each of the 18 individual criteria symptoms (both inattentive and hyperactive) of ADHD in DSMIV on a severity grid (0=not present; 3=severe; minimum score=0; maximum score=54). Results are given as average change (reduction) in AISRS symptoms from baseline to Week 6.</description>
        <time_frame>baseline and 6 Weeks</time_frame>
        <population>All analyses were intention to treat (ITT) with the last observation carried forward (LOCF) for subjects who did not complete the full study schedule. Baseline and endpoint AISRS scores were compared used paired t-tests. Statistical significance was determined at alpha level 0.05.</population>
        <group_list>
          <group group_id="O1">
            <title>Strattera (Atomoxetine)</title>
            <description>Atomoxetine monotherapy up o 1.2 mg/kg/day or 120 mg/day.</description>
          </group>
        </group_list>
        <measure>
          <title>The Adult AISRS</title>
          <description>The Adult AISRS was used to assess each of the 18 individual criteria symptoms (both inattentive and hyperactive) of ADHD in DSMIV on a severity grid (0=not present; 3=severe; minimum score=0; maximum score=54). Results are given as average change (reduction) in AISRS symptoms from baseline to Week 6.</description>
          <population>All analyses were intention to treat (ITT) with the last observation carried forward (LOCF) for subjects who did not complete the full study schedule. Baseline and endpoint AISRS scores were compared used paired t-tests. Statistical significance was determined at alpha level 0.05.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Strattera (Atomoxetine)</title>
          <description>Atomoxetine monotherapy up o 1.2 mg/kg/day or 120 mg/day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision/ocular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tired/fatigued</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lightheaded/dizzy</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Colds/allergies/infections</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Muscle twitch/tremor</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Warmth/flushing/sweating</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tension/jitteriness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Impaired concentration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Tingling sensation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Bad taste</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood change</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Vivid dreams</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary hesitancy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual function</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>small, open label study
short exposure to medication</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph Biederman, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-1743</phone>
      <email>jbiederman@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

